AmVision Biotech, a leading ophthalmology device platform company based in Guangzhou, has reportedly secured close to RMB 100 million (USD 14.34 million) in a Series A+ financing round. The round was led by Green Pine Capital Partners, with participation from ZDVC and existing investor HM Capital, among others. This significant funding will support the company’s ongoing development and expansion in the ophthalmology sector.
Company Background and Achievements
Founded in 2014, AmVision Biotech has established itself as a pioneer in the field of ophthalmology devices. The company holds the distinction of having the first approved cryopreserved biological amnion product in China, a significant achievement that highlights its commitment to innovation and quality. Additionally, AmVision Biotech has licensed the scleroscope product Epicon A from an Australian firm, which is expected to receive market approval in the first half of this year. This product addition further strengthens the company’s portfolio.
Product Development and Future Prospects
AmVision Biotech is not only focused on its current successes but is also actively developing a range of products in key areas of ophthalmology, including ocular surface, optometry, glaucoma, and fundus macular hole treatments. The Series A+ financing will provide the necessary capital to accelerate the development and commercialization of these innovative products, positioning the company for continued growth and leadership in the global ophthalmology market.-Fineline Info & Tech
